In general, EMT stimulates an adaptive immune response, characterized by a significant increase in CD3+ tumor-infiltrating lymphocytes and regulatory T cells in the tumor microenvironment (TME) along with inflammation-associated cytokines, like IL-6, IL-8, and TGF-β and multiple immune regulatory molecules, including PD-L1, altogether contributing to the immunosuppressive TME [6]. The gene discussed is CD274; the disease is neoplasm.